Issue

Vol. 64 No. 11: Issue 11

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Association between BIM polymorphism and lung cancer outcomes: a meta-analysis

https://doi.org/10.14715/cmb/2018.64.11.17
Xiao-feng Li
Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China
Li-xin Wu
Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China
Hua-fei Chen
Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China
You-cai Zhu
Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China
Wen-xian Wang
Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China
Chun-wei Xu
Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, People's Republic of China
Xue-ping Lin
Department of Pathology, Jiaxing University College of Medicine, Jiaxing Zhejiang 314000, People's Republic of China
Dong-fang Xie
Department of Pathology, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China
Kai-qi Du
Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China

Corresponding Author(s) : Xue-ping Lin

2359249340@qq.com

Cellular and Molecular Biology, Vol. 64 No. 11: Issue 11

Abstract

Accumulating evidences have indicated that BIM expression largely decides the development of lung cancer and outcome of EGFR-mutant lung cancers after TKI treatments. BIM polymorphism is a 2,903-bp deletion in the second exon. To clarify the relationship between this BIM polymorphism and clinical outcomes of lung cancers, we conducted this meta-analysis and observed the survival and responses to TKIs. Sixteen cohort studies, covering 4393 WT and 916 BIM deletion patients were included. Overall, BIM deletion polymorphism was associated with significantly shorter progression-free survival (PFS) and slightly shorter overall survival (OS), compared to the WT group. Moreover, patients with BIM deletion polymorphism showed significantly inferior response to EGFR TKIs. In conclusion, our analysis confirmed that lung cancer patients harboring the BIM deletion have inferior survival and TKI responses. Examination of the novel biomarker BIM deletion in lung cancer patients, especially for the EGFR mutant cohort, could provide some prognostic utility.

Keywords

BIM polymorphism Bcl-2-like 11 EGFR mutation Lung cancer Tyrosine kinase inhibitor.
Li, X.- feng, Wu, L.- xin, Chen, H.- fei, Zhu, Y.- cai, Wang, W.- xian, Xu, C.- wei, Lin, X.- ping, Xie, D.- fang, & Du, K.- qi. (2018). Association between BIM polymorphism and lung cancer outcomes: a meta-analysis. Cellular and Molecular Biology, 64(11), 92–96. https://doi.org/10.14715/cmb/2018.64.11.17
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. References
  2. Morgillo, F., et al., Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open, 2016. 1(3): p. e000060.
  3. Wang, J. and T. Xin, (Effect and Significance of BIM on Non-small Cell Lung Cancer). Zhongguo Fei Ai Za Zhi, 2016. 19(11): p. 789-792.
  4. Karachaliou, N., et al., BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep, 2015. 5: p. 17499.
  5. Sakakibara-Konishi, J., et al., Expression of Bim, Noxa, and Puma in non-small cell lung cancer. BMC Cancer, 2012. 12: p. 286.
  6. Simasi, J., et al., The role of BIM-EL and BCL2-alpha on the efficacy of erlotinib and gefitinib in lung cancer. Respir Physiol Neurobiol, 2015. 209: p. 64-8.
  7. Lee, J.K., et al., Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol, 2013. 24(8): p. 2080-7.
  8. Lee, J.Y., et al., The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol, 2015. 10(6): p. 903-9.
  9. Ng, K.P., et al., A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med, 2012. 18(4): p. 521-8.
  10. Cho, E.N., et al., BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis. Lung Cancer, 2015. 90(1): p. 106-10.
  11. Ebi, H., et al., Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. J Thorac Oncol, 2015. 10(1): p. 59-66.
  12. Zhou, Q., et al., A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung Cancer, 2014. 83(3): p. 369-73.
  13. Zhong, J., et al., Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients. Thorac Cancer, 2014. 5(6): p. 509-16.
  14. Zheng, L., et al., (Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor). Zhongguo Fei Ai Za Zhi, 2013. 16(12): p. 632-8.
  15. Zhao, M., et al., The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer, 2014. 120(15): p. 2299-307.
  16. Zhang, L., et al., Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cancer, 2017. 123(15): p. 2927-2935.
  17. Xia, J.J., et al., Real-time PCR assay with high resolution melting for EGFR and BIM mutation of lung cancer. Eur Rev Med Pharmacol Sci, 2016. 20(13): p. 2805-11.
  18. Takeuchi, S., et al., Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. J Med Invest, 2017. 64(3.4): p. 321-325.
  19. Qian, K., Y. Zhang, and X. Zhi, (Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma). Zhongguo Fei Ai Za Zhi, 2017. 20(8): p. 543-548.
  20. Lee, J.H., et al., Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol, 2014. 9(9): p. 1385-92.
  21. Kim, G.W., et al., Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer, 2015. 88(2): p. 139-46.
  22. Isobe, K., et al., Association of BIM Deletion Polymorphism and BIM-gamma RNA Expression in NSCLC with EGFR Mutation. Cancer Genomics Proteomics, 2016. 13(6): p. 475-482.
  23. Isobe, K., et al., Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation. J Thorac Oncol, 2014. 9(4): p. 483-7.
  24. Cardona, A.F., et al., BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016. 7(42): p. 68933-68942.
  25. Atsumi, J., et al., Impact of the Bim Deletion Polymorphism on Survival Among Patients With Completely Resected Non-Small-Cell Lung Carcinoma. J Glob Oncol, 2016. 2(1): p. 15-25.
  26. Huang, L. and L. Fu, Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 2015. 5(5): p. 390-401.
  27. Nie, W., et al., The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis. Oncotarget, 2015. 6(28): p. 25696-700.
  28. Ying, H.Q., et al., The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. Sci Rep, 2015. 5: p. 11348.
  29. Zou, Q., et al., The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. Transl Lung Cancer Res, 2015. 4(6): p. 792-6.
  30. Soh, S.X., et al., A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget, 2017. 8(25): p. 41474-41486.
  31. Sun, S., et al., Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Onco Targets Ther, 2017. 10: p. 1955-1967.
  32. Huang, W.F., et al., BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 2015. 94(33): p. e1263.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 813 Download : 335